INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Maxim Group Analyst Says

INmune Bio (NASDAQ:INMB - Get Free Report) had its price target increased by equities research analysts at Maxim Group from $22.00 to $30.00 in a report issued on Thursday,Benzinga reports. The firm currently has a "buy" rating on the stock. Maxim Group's target price would indicate a potential upside of 226.80% from the stock's previous close.

A number of other equities research analysts also recently issued reports on INMB. Alliance Global Partners assumed coverage on shares of INmune Bio in a report on Monday, October 21st. They issued a "buy" rating and a $20.00 target price for the company. Rodman & Renshaw assumed coverage on shares of INmune Bio in a report on Tuesday, January 28th. They issued a "buy" rating and a $23.00 target price for the company. Scotiabank boosted their target price on shares of INmune Bio from $22.00 to $23.00 and gave the company a "sector outperform" rating in a report on Tuesday, February 11th. Finally, RODMAN&RENSHAW upgraded shares of INmune Bio to a "strong-buy" rating in a report on Tuesday, January 28th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $22.80.

INmune Bio Trading Down 1.3 %

Shares of NASDAQ INMB traded down $0.12 during midday trading on Thursday, reaching $9.18. 311,175 shares of the stock were exchanged, compared to its average volume of 514,959. The company has a market capitalization of $203.52 million, a P/E ratio of -4.21 and a beta of 1.87. INmune Bio has a 52-week low of $4.32 and a 52-week high of $14.49. The stock has a 50 day moving average price of $6.69 and a 200-day moving average price of $6.11.

Institutional Investors Weigh In On INmune Bio

Several institutional investors have recently bought and sold shares of the business. Praetorian PR LLC grew its stake in INmune Bio by 61.0% during the third quarter. Praetorian PR LLC now owns 780,800 shares of the company's stock worth $4,209,000 after buying an additional 295,800 shares during the period. Raymond James Financial Inc. purchased a new stake in INmune Bio during the fourth quarter worth approximately $2,221,000. Geode Capital Management LLC grew its stake in INmune Bio by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 363,602 shares of the company's stock worth $1,698,000 after buying an additional 19,136 shares during the period. Millennium Management LLC grew its stake in INmune Bio by 43.9% during the fourth quarter. Millennium Management LLC now owns 291,327 shares of the company's stock worth $1,360,000 after buying an additional 88,823 shares during the period. Finally, State Street Corp lifted its position in shares of INmune Bio by 35.1% during the third quarter. State Street Corp now owns 226,428 shares of the company's stock worth $1,220,000 after purchasing an additional 58,838 shares in the last quarter. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.